Galera Therapeutics Inc. (NASDAQ: GRTX) 52-Week High Located At $3.59, Forget The Dips, Just Ride The Rips

Galera Therapeutics Inc. (NASDAQ:GRTX) does about 2.21M shares in volume on a normal day but saw 3496464 shares change hands in Friday trading. The company now has a market cap of 10.21M USD . Its current market price is $0.22, marking a decrease of -4.65% compared to the previous close of $0.23. The 52 week high reached by this stock is $3.59 whilst the lowest price level in 52 weeks is $0.23. The script in recent trading has seen the stock touch a high of $0.2353 and a low of $0.2163.

Galera Therapeutics Inc. (GRTX) has a 20-day trading average at $1.6163 and the current price is -93.84% off the 52-week high compared with -4.61% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.4193 and its 200-day simple moving average is $2.2614. If we look at the stock’s price movements over the week, volatility stands at 11.99%, which decreases to 11.06% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 15.57 to suggest the stock is oversold.

3 analysts observing the Galera Therapeutics Inc. (GRTX) stock have set the 12-month price targets for the company’s shares at between $0.30 and $0.50. The median price target is 45.0% away from the current levels at $0.40.

FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 0 analysts have rated it as a buy and 3 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Hold the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 10, 2023 when Piper Sandler downgraded the stock to “Neutral” and issued a price target of between $6 and $0.50.

The current price level is -87.30%, -91.06%, and -90.24% away from its SMA20, SMA50, and SMA200 respectively, with the GRTX price moving above the 50-day SMA on August 18. Galera Therapeutics Inc. (GRTX) stock is down -31.32% over the week and -92.12% over the past month. Its price is -85.15% year-to-date and -84.30% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2023, with the company’s earnings per share (EPS) of -$0.48 below consensus estimates by -$0.1. The company’s next earnings report is expected on 11/08/2023, with forecasts estimating quarterly EPS at -$0.4 and -$1.64 for whole year. GRTX’s earnings per share are forecast to grow by 28.70% this year and 51.80% over next year.

Its 12-month price target is $0.40. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $0.30, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $0.50.

The company has a return on equity of 67.40%. The beta has a value of 2.06.

According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market ETF has added its position in Galera Therapeutics Inc. (GRTX) to 1,126,998 shares, mirroring a recent increase by 7.07%. Vanguard Total Stock Market ETF added 74400.0 shares of Galera Therapeutics Inc. common stock bringing its total worth to about $2.77 million at the end of recent close, SEC documents show. Vanguard Total Stock Market ETF isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which added 0.11 million shares to end up with 432,030 shares worth $1.06 million. Variopartner SICAV – Sectoral Hea cut their holdings by -10.09% in the company over the course of the most recent quarter. It now holds a 0.75% position in Galera Therapeutics Inc. thanks to 0.32 million shares amounting to $0.79 million.